NeoTCR P201
Alternative Names: NeoTCR-P201Latest Information Update: 28 Aug 2026
At a glance
- Originator PACT Pharma
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Bladder cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer; Skin cancer
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Bladder-cancer in USA (Parenteral, Infusion)
- 28 Aug 2026 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral, Infusion)
- 28 Aug 2026 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral, Infusion)